Navigation Links
Gene Test Might Predict Tamoxifen's Effectiveness
Date:10/6/2009

The breast cancer drug works better depending on particular DNA, study suggests

TUESDAY, Oct. 6 (HealthDay News) -- A genetic variant seems to predict resistance to the breast cancer drug tamoxifen, German researchers report.

The findings, which appear in the Oct. 7 issue of the Journal of the American Medical Association, could allow clinicians to predict which women will benefit most from the drug, which has been the gold standard of breast cancer care for the past 25 years. Women who do carry the gene variant may be candidates for alternative treatments.

The gene affects the activity of the CYP2D6 enzyme, which converts tamoxifen into its metabolite, endoxifen. It is this metabolite that allows the drug to work its magic against breast tumors.

"This is really the largest study that's been done in this area," noted V. Craig Jordan, scientific director of Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C. "It's now clear if you don't have the ability to create endoxifen out of tamoxifen, you don't have a good response rate. This is really important because for women who are taking the drug for five years, you better know it's going to work for you."

And for women who won't have the desired therapeutic response to tamoxifen, there are now other options, namely in the form of medicines called aromatase inhibitors, which, like their older cousin tamoxifen, inhibit the effect of estrogen on cancer.

"In postmenopausal women, if you've got this aberration in your metabolism of tamoxifen, you could be offered an aromatase inhibitor, so there is something one could do for a person at this particular point," Jordan said.

Jordan is known as the "father of tamoxifen" because he helped develop the drug.

On the other hand, if your body is able to metabolize tamoxifen effectively, Jordan added, "it's as good a therapy as you can get."

Although tamoxifen has an excellent track record, many women do develop resistance to the drug. And researchers are in the process of calibrating when tamoxifen might be more appropriate to a situation and when aromatase inhibitors would better serve the patient.

The authors looked back at the cases of 1,325 women, almost all postmenopausal, who had been diagnosed with estrogen-receptor-positive, early-stage breast cancer.

Women were tested for CYP2D6 variants and divided into three groups based on the results: extensive metabolizers, extensive/intermediate metabolizers or poor metabolizers.

After an average follow-up of 6.3 years, women who were better metabolizers of CYP2D6 were less likely to see their cancer recur: 14.9 percent versus 20.9 percent in the intermediate group and 29 percent in the poor-metabolizer group. Low metabolizers also had lower rates of event-free survival, but no difference in overall survival. The authors did point out that the follow-up period was not long enough to actually determine differences in overall survival.

One expert had a mixed response to the new findings.

"I think this is real. I think these variants have some impact on how effective tamoxifen is for a given woman, but I don't think it's an all or nothing, either you respond or you don't. I think there are gradations of response," said Dr. Mary Daly, senior vice president of population science and director of the Cancer Prevention and Control Program at Fox Chase Cancer Center in Philadelphia.

But she also said she would like to see prospective studies before changing how she practices medicine.

"I'm not too sure how important this will be clinically because we're all sort of switching to aromatase inhibitors anyway," she added. "In general, though, it signals a movement towards personalizing therapies to genetic variants."

For his part, Jordan predicts that using genetic testing to help determine treatment will become the standard of care within just six months to a year. The cost should not be prohibitive, he added, especially as the test becomes more widely available.

Five of the study authors, in conjunction with the Mayo Clinic, have filed patent applications related to tamoxifen and CYP2D6.

More information

There's more on tamoxifen at the U.S. National Cancer Institute.



SOURCES: V. Craig Jordan, Ph.D., D.Sc., scientific director, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C.; Mary Daly, M.D., Ph.D., senior vice president, population science and director, Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia; Oct. 7, 2009, Journal of the American Medical Association


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Simple Test Might Detect Silent Heart Disease
2. Alcohol Might Lower Death Rates in Brain Injury Patients
3. Sleep Deprivation Might Lead to Alzheimers
4. Computers Might Make Learning Lip Reading Easier
5. Thin Thighs Might Be Harbinger of Heart Disease
6. MRI Might Find Early Alzheimers
7. Pot Might Blunt Damage of Binge Drinking
8. Blood Pressure Drug Might Work Against MS
9. If Baby Is Breech, Technology Might Help
10. Low Birth Weight Might Raise Adult Kidney Disease Risk
11. Plastic Surgery Technique Might Ease Migraines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
(Date:2/10/2016)... ... ... Gout is like no other joint pain. It strikes suddenly, like flicking on ... redness. It is triggered by the crystallization of uric acid within the joints. It ... to the February 2016 issue of Harvard Men's Health Watch. , The large joint ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged ... Research shows that the Goal Attainment Scale (GAS) captures 20% more change in ... learn more about the Goal Attainment Scale, Education Resources Inc. is offering a ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... make Everseat digital self-scheduling readily available to physicians. The integration will ... can find and select appointments via Everseat’s free mobile app. , The partnership ...
(Date:2/10/2016)... ... ... Workrite Ergonomics, who is celebrating their 25th year of business in 2016, ... internationally recognized leader in their industry. , "We are very proud of our heritage ... “Workrite recognized the importance of good ergonomics before most of our competition even ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 10, 2016   Genomic Health, Inc. (Nasdaq: GHDX ... and year ended December 31, 2015. --> ... of 2015, compared with $69.1 million in the fourth quarter of ... revenue increased 9 percent compared with the same period in the ... revenue was $63.9 million in the fourth quarter of 2015, an ...
(Date:2/10/2016)... Calif. , Feb. 10, 2016  Cepheid ... Warren Kocmond , formerly Executive Vice President and ... position of President and Chief Operating Officer.  In ... expanded, and now include Global Commercial Operations in ... Customer Service.  Mr. Kocmond will continue to report ...
(Date:2/10/2016)... och PITTSBURGH , 10 ... inte, och detta pressmeddelande får inte distribueras, ... till, och inga anmälningssedlar kommer att accepteras ... något land där Erbjudandet, distribution av detta ... skulle strida mot tillämpliga lagar eller regler ...
Breaking Medicine Technology: